Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258236 | 1.00 | KMT2A (0.48) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL258289 | 0.98 | — | — | |
| SCHEMBL258148 | 0.90 | — | — | |
| SCHEMBL258218 | 0.82 | KMT2A (0.45) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL3291610 | 0.80 | CA1 (0.48) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL911028 | 0.79 | — | — | |
| SCHEMBL258305 | 0.79 | CA1 (0.43) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL23607890 | 0.74 | NOS3 (0.39) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL10867159 | 0.74 | NOS3 (0.39) | KMT2ACA1CA2CA4NOS3 | |
| SCHEMBL258120 | 0.74 | NOS3 (0.39) | KMT2ACA1CA2CA4NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156387-B1 | METHOD OF PREPARING INDENE DERIVATIVES | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2018-07-25 | — | — | EP | disclosed |
| EP-3156387-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | Aquinox Pharmaceuticals (Canada) Inc. (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2277848-B1 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS CANADA INC (CA) | 2016-09-14 | — | — | EP | disclosed |
| US-20150307426-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2015-10-29 | — | — | US | disclosed |
| US-20140371252-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-12-18 | — | — | US | disclosed |
| US-8673975-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20120270901-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-8084503-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-12-27 | — | — | US | disclosed |
| US-7999010-B2 | Indene derivatives as pharmaceutical agents | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-08-16 | — | — | US | disclosed |
| US-20110172258-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | AQUINOX PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2005-01-06 | — | — | US | disclosed |
| WO-2004092100-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-10-28 | — | — | WO | disclosed |
| US-20040162425-A1 | 6,7-Oxygenated steroids and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| US-20040157814-A1 | 6, 7-Oxygenated steroids and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-08-12 | — | — | US | disclosed |
| US-6706701-B1 | SAFE AND EFFECTIVE RELIEF OF ASTHMA AND ALLERGY SYMPTOMS | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-03-16 | — | — | US | disclosed |
| EP-1304333-A2 | 6,7-Oxygenated steroids and uses related thereto | Inflazyme Pharmaceuticals, Ltd. (CA) | 2003-04-23 | — | — | EP | disclosed |
| EP-0917534-B1 | 6,7-OXYGENATED STEROIDS AND USES RELATED THERETO | INFLAZYME PHARM LTD (CA) | 2002-12-04 | — | — | EP | disclosed |
| US-6046185-A | 6,7-oxygenated steroids and uses related thereto | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2000-04-04 | — | — | US | disclosed |
| EP-0917534-A2 | 6,7-OXYGENATED STEROIDS AND USES RELATED THERETO | Inflazyme Pharmaceuticals, Ltd. (CA) | 1999-05-26 | — | — | EP | disclosed |
| WO-1998002450-A2 | 6,7-OXYGENATED STEROIDS AND USES RELATED THERETO | INFLAZYME PHARMACEUTICALS LTD. (CA) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162425-A1 | 6,7-Oxygenated steroids and uses related thereto | CYP11B1, CYP11B2, CYP21A2 | KMT2A 4574/4885CA1 860/4885CA2 2722/4885 |
| US-20150307426-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSRR, INSR, IDO1 | KMT2A 3901/4885CA1 4691/4885CA2 4291/4885 |
| US-20120270901-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSR, INSRR, F12 | KMT2A 2914/4885CA1 3931/4885CA2 3189/4885 |
| US-20040157814-A1 | 6, 7-Oxygenated steroids and uses related thereto | CYP11B1, CYP11B2, CYP21A2 | KMT2A 4574/4885CA1 860/4885CA2 2722/4885 |
| US-20110172258-A9 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSR, INSRR, F12 | KMT2A 2878/4885CA1 3984/4885CA2 3263/4885 |
| US-20050004086-A1 | Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease | IDO1, URB2, ARG1 | KMT2A 4419/4885CA1 3590/4885CA2 4710/4885 |
| US-20140371252-A1 | INDENE DERIVATIVES AS PHARMACEUTICAL AGENTS | INSRR, INSR, IDO1 | KMT2A 3901/4885CA1 4691/4885CA2 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.